Our Team
E. Russell McAllister
Chief Executive Officer
- More than 20 years of biopharma industry experience, focusing on corporate strategy and business development
- Current CEO, Intezyne (Oncology); Former CFO, Intezyne (Oncology); Qu Biologics (Immuno-oncology) and Lakewood-Amedex (Infectious disease)
- 2018 CFO of the Year Honoree, Tampa Bay Business Journal (TBBJ)
- 2017 ‘Deal of the Year’ recipient; Southeast Bio (SEBIO)
- Former Managing Director, Head of Healthcare Strategic Advisory, H.C. Wainwright / Rodman & Renshaw
- 5-Star-Rated Senior Equity Research Analyst (Biopharmaceuticals), Merriman Curhan Ford & Co. and Thomas Weisel Partners (Stifel)
- PhD candidate, Behavioral Finance, University of Illinois; MS Accounting / MBA, Northeastern University
Jim Pankovich
Executive Vice President, Clinical Development
- More than 25 years of biopharma industry experience, focusing on clinical study strategy and management.
- Former VP, Clinical Operations and Drug Development, Qu Biologics (Immuno-oncology); CSO, CIHR Canadian HIV Trial Network (Infectious disease); Sr Director, Clinical Research, Migenix (Infectious disease); Assc Director, Clinical Research, Inex Pharmaceuticals (Oncology)
- MS, Experimental Medicine, University of Alberta
- MBA, Queen’s University
Michelle Jones
Director, Clinical Development
- More than 15 years of biopharma industry experience, focusing on clinical trial management and operations.
- Former Associate Director, Clinical Operations, Qu Biologics (Immuno-oncology); Clinical Operations Manager, Symvivo (Immuno-oncology); Research Manager, CIHR Canadian HIV Trial Network (Infectious disease); Clinical & Regulatory Affairs Manager, Protiva Biotherapeutics (Oncology & Infectious disease)
- MSc, Nursing, McGill University
- MBA (Management of Biotechnology Specialization), Simon Fraser University
Mark Bazett, PhD
Director, Preclinical Development
- 5 years of biopharma industry experience, focusing on preclinical development.
- Former Preclinical Immunotherapy Lead, Novelogics (Oncology); Director of Preclinical and Translational Research, Qu Biologics (Immuno-oncology)
- PhD, Immunology, McGill University
Adam Carie, PhD
Director of CMC & Nonclinical Development
- More than 10 years biopharma industry experience developing novel oncology therapeutics, including IVECTTM™ polymer nanoparticle technology from concept to clinic.
- More than 10 years of biopharma industry experience, focusing on oncology product development, formulation, optimization, logistics and manufacturing.
- Focus on nonclinical development, manufacturing, quality systems, supply chain management, logistics, and regulatory support.
- Current Director of Product Development for Intezyne, also managed CMC for BOLD-100 during development at Intezyne.
- PhD in Cancer Biology from University of South Florida. PhD research in Cancer Drug Discovery at H. Lee Moffitt Cancer Center in Tampa, FL.
Melissa Smith
Office Manager
- BA, Criminology (Concentrations: Psychology and Sociology), University of the Fraser Valley
- AA, Kinesiology (Concentrations: Anatomy and Physiology), Langara College
- Responsible for office management, conference and travel logistics, and providing support for accounting, business development, finance and investor relations.
Carly Hastings
Operations Associate
- BS, Health Sciences (Concentrations: Health Management and Biological Sciences), University of South Florida
- Responsible for accounting, clinical trial logistics and procurement, as well as providing support for business development, finance and investor relations.
Elizabeth Daley
Executive Assistant
- BS, Cell and Molecular Biology, University of South Florida (May 2020).
- BS, Health Sciences (Concentration: Health Management), University of South Florida (May 2020).
- Experience in managing administrative duties, assisting with project management, accounting, and investor relations.
- Responsible for competitive intelligence and providing support for accounting, business development, and investor relations.